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| INTRODUCTION
Venous thromboembolism (VTE) affects between 1% and 8% of all patients undergoing cancer therapy and is the second leading cause of death among outpatients undergoing chemotherapy. 1, 2 Management of cancer-associated thrombosis (CAT) requires special considerations and is different from the management of VTE in non-cancer patients. 3 It is made more challenging by the presence of other complications of cancer therapy, such as thrombocytopenia, which is common among patients undergoing chemotherapy for hematologic malignancy and certain solid tumors. While thrombocytopenia has not shown any protective benefits against recurrent VTE among CAT patients, it has been associated with increased rates of bleeding. 4 Therefore, the management of anticoagulation in this patient population requires special attention.
Low-molecular-weight heparin (LMWH) is known to reduce the risk of VTE recurrence and is currently recommended by all clinical
practice guidelines for the initial treatment of CAT. 5 However, its optimal dosing for the management of CAT in patients with thrombocytopenia is unknown. Whereas some studies suggest that administration of reduced-dose LMWH for moderate thrombocytopenia (platelet counts <50 × 10 9 /L) and temporary discontinuation for severe thrombocytopenia (platelet counts <25 × 10 9 /L) may be a safe and effective, others suggest full-dose anticoagulation with transfusion support in thrombocytopenia. 6, 7 We sought to address this important knowledge gap and summarize the literature comparing these two common management strategies for the management of anticoagulation in the setting of CAT and thrombocytopenia: full dose anticoagulation with platelet support and dose-modified LMWH.
| METHODS
This systematic review was registered on PROSPERO (registration number CRD42017077127 
| RESULTS AND DISCUSSION
A total of 134 article records were identified on the initial search and 10 articles underwent full text review. Of these, six were excluded for failing to include patients undergoing management according to both treatment strategies, 6,10-14 one was excluded for failure to report outcomes of both strategies 7 and one was excluded for study design (case series of only five patients). 15 The remaining two studies were included and are described below. Ten studies which were excluded due to only utilizing one treatment strategy are outlined in Table 1 for comparison. 12, [15] [16] [17] [18] [19] [20] Overall, 121 patients with CAT and thrombocytopenia were included in our review (Table 2) . Forty-two of these patients had pulmonary embolism (PE) and 87 had deep vein thrombosis (DVT) including 38 upper extremity DVT (several patients had multiple events at different locations).
The first study was a retrospective cohort study of 74 patients with CAT and thrombocytopenia defined as a platelet count Table 2 ).
The majority of recurrent VTE events occurred in patients receiving
Essentials
• The management of anticoagulation in patients with thrombocytopenia is controversial.
• Some studies suggest to administer reduced-dose low-molecular-weight heparin (LMWH).
• While other studies suggest full-dose anticoagulation using LMWH and transfusion support.
• The results from our systematic review do not support one management strategy over another. Eleven and 5 patients had a recurrent VTE and major bleeding episode, respectively ( Table 2) . Four of the five major bleeding events occurred in patients receiving therapeutic anticoagulation. Two of the 11 recurrent VTE events occurred in patients receiving therapeutic anticoagulation.
A quality assessment of each study was performed using the ROBINS-1 method. 25 Both studies were judged to be at serious risk of bias in two domains (confounding and selection of reported results) but not at critical risk of bias in any domain. The rate of major bleeding episodes, on the other hand, was more modest and nearly half the reported rate of recurrent VTE.
Thirteen percent of anticoagulated patients (15% of all patients) experienced a major bleeding episode. This rate is consistent with a previously published study among patients with treatment-related thrombocytopenia not receiving anticoagulation. desperately needed to adequately compare these two anticoagulation management strategies and provide guidance to clinicians.
Our review has a number of limitations, the most important one is the small number of included studies and lack of any randomized, controlled trials. Additionally there was a large degree of heterogeneity between studies, including population (thrombocytopenia defined differently), intervention (dosing) length of follow-up and definition of outcomes. This, in addition to the small sample size, prohibited pooling of data.
In conclusion, our findings do not support one management strategy over another to treat CAT patients with thrombocytopenia.
However, the data highlights the heightened risk of recurrent VTE in this patient population despite the thrombocytopenia. Therefore, clinicians should consider initiating anticoagulation (therapeutic or reduced-dose LMWH) in the absence of absolute contraindications for these patients. 
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